Clinical and Research Background
Dr. Frenkel’s group performs clinical, translational and basic laboratory research on mechanisms of HIV persistence and HIV drug resistance. Past work refuted the concept of transient HIV infection in infants (Science, 1998; PMID 9582120); was first to suggest (J Viro 2005, PMID 16014925) and later provide proof that proliferating cells that have a major role in sustaining the HIV reservoir despite effective treatment; (J Virol 2013, PMID 23175380; Science 2014, PMID 25011556), including that which rekindles infection following ART suspension (PLoS Pathog 2020, PMID 32841299). Our finding that HIV is integrated disproportionately into genes that control immune functions, the cell cycle, cancers or pathways controlling T-regulatory cells (J Infect Dis2017, PMID 28520966) has led to current projects investigating HIV reservoirs effects on (1) cervical cancer, (2) immune tolerance of HIV infants, (3) immune activation, and (4) HIV rebound after ART suspension.
Our group’s research on HIV drug resistance have defined reservoirs and effects of mutant codons (Clin Infect Dis 2010, PMID 20377404) as well as the utility of point mutation assays in screening to diagnose HIV drug resistance (Lancet HIV 2019, PMID 32386719); and current studies aim to define the mutant codons and the frequencies associated with failure of dolutegravir-based treatments in low-resource settings and to develop inexpensive assays to detect (Panpradist, EBioMedicine 2019 PMID 31767540 and AIDS PMID 32205723.
Education and Training
Infectious Disease Fellowship, University of California, Los Angeles, California, 1984-87
Pediatric Residency, University of California, Los Angeles, California, 1981-84
MD, Kansas University Medical School, Kansas City, Kansas, 1977-81
BA, Kansas University, Lawrence, Kansas, 1973-77
Universidad de Costa Rica, San Jose, 1976-77
Latest publications from PubMed